AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23680226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - 1 g intravenously as a bolus immediately after randomization, followed by continuous infusion of 1 g per 8 hours until aneurysm treatment or maximum of 24 hours.
Number of subjects: 950
Study 23680226 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without TXA.
Number of subjects: 950
Study 20525844 — intervention group
Group type: EXPERIMENTAL
Intervention: DAREA score
Number of subjects: 0
Study 19140662 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive prior contact with grandchildren (Experiment 1)
Number of subjects: 135
Study 19140662 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined intergenerational contact (Experiment 2)
Number of subjects: 135
Study 16925104 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating proteins (epoetin alfa, epoetin beta, darbepoetin alfa)
Number of subjects: 0
Study 16925104 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment of mild anemia with erythropoietic therapy
Number of subjects: 0
Study 16925104 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietic therapy
Number of subjects: 0
Study 12958322 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole 400 mg/d
Number of subjects: 591
Study 12958322 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 30 to 325 mg/d
Number of subjects: 591
Study 11190751 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expiration through the nose (PNEF) in NANIPER patients
Number of subjects: 30
Study 11190751 — intervention group
Group type: COMPARATOR
Intervention: Forced expiration through the nose (PNEF) in controls
Number of subjects: 30
Study 9150630 — intervention group
Group type: EXPERIMENTAL
Intervention: The Images Within program (experimental group)
Number of subjects: 588
Study 9150630 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 588
Study 7514030 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) (Filgrastim) at a dose of 5 micrograms/kg/day i.m. from day 6 to day 19
Number of subjects: 19
Study 7514030 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (DHAD) 12 mg m-2 i.v. on day 1; Ifosfamide (IFO) 4 g m-2 i.v. on days 1 and 2; Mesna 800 mg m-2 i.v. t.i.d. on days 1 and 2
Number of subjects: 19
Study 3502542 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine
Number of subjects: 32
Study 3502542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 32
Study 29268948 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks
Number of subjects: 931
Study 29268948 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (vinflunine 320 mg/m2, paclitaxel 175 mg/m2, or 75 mg/m2 docetaxel) every 3 weeks
Number of subjects: 931
Study 26788432 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile devices corresponding to their condition(s) (hypertension: Withings Blood Pressure Monitor; diabetes: Sanofi iBGStar Blood Glucose Meter; arrhythmia: AliveCor Mobile ECG) and an iPhone with linked tracking applications for 6 months.
Number of subjects: 0
Study 26788432 — intervention group
Group type: COMPARATOR
Intervention: Standard disease management program (Control group)
Number of subjects: 0
Study 26788432 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile devices and online health management system (Intervention group)
Number of subjects: 0
Study 23601128 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 28
Study 23601128 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy core stability exercises
Number of subjects: 28
Study 23601128 — intervention group
Group type: EXPERIMENTAL
Intervention: FES combined with physiotherapy
Number of subjects: 28
Study 23601128 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding gluteal stimulation to FES
Number of subjects: 28
Study 23455538 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual removal of placenta
Number of subjects: 100
Study 23455538 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous removal of placenta
Number of subjects: 100
Study 23455538 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 20636964 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic cream (EMLA) applied to the lower leg for 1.5 hours
Number of subjects: 37
Study 20636964 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied to the lower leg for 1.5 hours
Number of subjects: 37
Study 20636964 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic cream (EMLA)
Number of subjects: 37
Study 18402899 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 10001
Study 18402899 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 10001
Study 17240783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) meal, 2 g/kg body mass CHO, ingested 3 hours prior to exercise
Number of subjects: 8
Study 17240783 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Index (HGI) meal, 2 g/kg body mass CHO, ingested 3 hours prior to exercise
Number of subjects: 8
Study 12834935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine intravenously (N=90)
Number of subjects: 185
Study 12834935 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine orally (N=95)
Number of subjects: 185
Study 10962124 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme
Number of subjects: 24
Study 10962124 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme in idiopathic dilated cardiomyopathy
Number of subjects: 24
Study 8964192 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiatherosclerosis interventions
Number of subjects: 0
Study 8964192 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard lipids (total cholesterol and LDL-cholesterol)
Number of subjects: 0
Study 8964192 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride-rich lipoproteins
Number of subjects: 0
Study 8964192 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial coronary angiography
Number of subjects: 0
Study 8964192 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ultrasonographic measures of carotid intima-media thickness
Number of subjects: 0
Study 8173309 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 IU rhGH/kg/day
Number of subjects: 39
Study 8173309 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 IU rhGH/kg/day
Number of subjects: 39
Study 8173309 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 IU rhGH/kg/day
Number of subjects: 39
Study 8173309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3815173 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominopelvic computerized tomography
Number of subjects: 30
Study 3815173 — intervention group
Group type: EXPERIMENTAL
Intervention: Open peritoneal lavage
Number of subjects: 30
Study 3815173 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 30
Study 3815173 — intervention group
Group type: COMPARATOR
Intervention: Negative findings on laparotomy
Number of subjects: 30
Study 31944084 — intervention group
Group type: EXPERIMENTAL
Intervention: Endophytic rhizobacteria treatment
Number of subjects: 10
Study 30093516 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced rehabilitation package (patient‐held information workbook, goal‐setting diary, and up to six additional therapy sessions)
Number of subjects: 61
Study 30093516 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation care (control)
Number of subjects: 61
Study 30093516 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced rehabilitation package
Number of subjects: 61
Study 28003026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led OA clinic training program
Number of subjects: 0
Study 28003026 — intervention group
Group type: COMPARATOR
Intervention: Pre-training questionnaire
Number of subjects: 0
Study 25343577 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural mimicry by the virtual interaction partner during a conversation about a sensitive conflict issue
Number of subjects: 60
Study 25343577 — intervention group
Group type: COMPARATOR
Intervention: Counter-mimicry condition
Number of subjects: 60
Study 22642755 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured programme of dietary advice over 24 weeks
Number of subjects: 27
Study 22642755 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 27
Study 22642755 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured programme of dietary advice
Number of subjects: 27
Study 20860572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 34
Study 20860572 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 34
Study 19083390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed rice (BRBL group)
Number of subjects: 40
Study 19083390 — intervention group
Group type: COMPARATOR
Intervention: White rice (WR group)
Number of subjects: 40
Study 16824240 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+) ketamine (0.05 mg kg‐1, 1.0 mL)
Number of subjects: 90
Study 16824240 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (25 microg, 1.0 mL)
Number of subjects: 90
Study 16824240 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (1.0 mL)
Number of subjects: 90
Study 12865483 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hypertension in subjects aged 80 years and older
Number of subjects: 0
Study 12865483 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment of hypertension in those aged 80 years and older
Number of subjects: 0
Study 11291605 — intervention group
Group type: EXPERIMENTAL
Intervention: C4 serum concentration in hypertensive patients
Number of subjects: 81
Study 11291605 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA, IgG, IgM serum concentrations in hypertensive patients
Number of subjects: 81
Study 11291605 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hypertension
Number of subjects: 81
Study 11291605 — intervention group
Group type: EXPERIMENTAL
Intervention: C4 serum concentration
Number of subjects: 81
Study 11291605 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA, IgG, IgM immunoglobulins
Number of subjects: 81
Study 8780336 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula PO/S (53% palm olein and 47% soy oil)
Number of subjects: 11
Study 8780336 — intervention group
Group type: COMPARATOR
Intervention: Formula S/C (60% soy oil and 40% coconut oil)
Number of subjects: 11
Study 1502399 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-intake related factors
Number of subjects: 234
Study 1502399 — intervention group
Group type: COMPARATOR
Intervention: Control group (234 controls)
Number of subjects: 234
Study 6838744 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 2-3.5 ml
Number of subjects: 33
Study 6838744 — intervention group
Group type: EXPERIMENTAL
Intervention: heavy cinchocaine
Number of subjects: 33
Study 30786754 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg for the first 4 weeks, then force-titrated to 25 mg until week 24)
Number of subjects: 150
Study 30786754 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 150
Study 30786754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 29856004 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5069 (0.1-200 mg single dose or 10-120 mg multiple doses)
Number of subjects: 240
Study 29856004 — intervention group
Group type: COMPARATOR
Intervention: AZD5069 (high-fat, high-calorie meal effect)
Number of subjects: 240
Study 29856004 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5069 (twice-daily dosing)
Number of subjects: 240
Study 29856004 — intervention group
Group type: COMPARATOR
Intervention: AZD5069 (age effect)
Number of subjects: 240
Study 29856004 — intervention group
Group type: COMPARATOR
Intervention: AZD5069 (ethnicity effect)
Number of subjects: 240
Study 29856004 — intervention group
Group type: COMPARATOR
Intervention: AZD5069 (co-administration with ketoconazole)
Number of subjects: 240
Study 29856004 — intervention group
Group type: COMPARATOR
Intervention: AZD5069 (various formulations)
Number of subjects: 240
Study 27599475 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI z-scores in pre-menarcheal girls
Number of subjects: 533
Study 27599475 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and height in girls aged 13-14 years who reached menarche
Number of subjects: 533
Study 27129007 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of allopurinol (200 mg)
Number of subjects: 24
Study 27129007 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of allopurinol (200 mg)
Number of subjects: 24
Study 22650250 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless capsule pH‐metry (WC)
Number of subjects: 86
Study 22650250 — intervention group
Group type: COMPARATOR
Intervention: Standard nasal pH catheter (SC)
Number of subjects: 86
Study 22650250 — intervention group
Group type: EXPERIMENTAL
Intervention: ESM + WC
Number of subjects: 86
Study 22650250 — intervention group
Group type: EXPERIMENTAL
Intervention: EGD + WC
Number of subjects: 86
Study 22650250 — intervention group
Group type: COMPARATOR
Intervention: ESM + SC
Number of subjects: 86
Study 21048707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral microdose of (14)C-labeled acetaminophen (AAP)
Number of subjects: 0
Study 21048707 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0
Study 17907648 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical scale
Number of subjects: 0
Study 17907648 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal rating scale
Number of subjects: 0
Study 17907648 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogy scale
Number of subjects: 0
Study 17907648 — intervention group
Group type: EXPERIMENTAL
Intervention: Face scale
Number of subjects: 0
Study 15714423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 15714423 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 0
Study 12484676 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert tutors (defined by previous tutorial experience)
Number of subjects: 0
Study 12484676 — intervention group
Group type: COMPARATOR
Intervention: Nonexpert tutors
Number of subjects: 0
Study 9484756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at a dose of 800 mg/day, then 1200 mg/day
Number of subjects: 140
Study 9484756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 7648765 — intervention group
Group type: EXPERIMENTAL
Intervention: E3810 (20 mg)
Number of subjects: 15
Study 7648765 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 15
Study 7648765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2541637 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (Phe) 50 micrograms
Number of subjects: 18
Study 2541637 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (Phe) 100 micrograms
Number of subjects: 18
Study 2541637 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (Phe) 150 micrograms
Number of subjects: 18
Study 2541637 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (Phe) 200 micrograms
Number of subjects: 18
Study 358021 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincamine hydrochloride, administered intramuscularly for 10 days
Number of subjects: 20
Study 358021 — intervention group
Group type: COMPARATOR
Intervention: Dihydrogenated ergotoxine derivative, administered intramuscularly for 10 days
Number of subjects: 20
Study 31181221 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits (HVs) by community health workers (CHWs) over 6 months
Number of subjects: 301
Study 31181221 — intervention group
Group type: COMPARATOR
Intervention: Usual care and portal training only
Number of subjects: 301
Study 28218553 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from family, friends, and health professionals
Number of subjects: 356
Study 28218553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft-related comments and/or teasing
Number of subjects: 356
Study 28218553 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about child's future
Number of subjects: 356
Study 28218553 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support
Number of subjects: 356
Study 25956401 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm ischemic preconditioning (BAIPC)
Number of subjects: 58
Study 25956401 — intervention group
Group type: COMPARATOR
Intervention: Sham BAIPC (Control)
Number of subjects: 58
Study 22753810 — intervention group
Group type: EXPERIMENTAL
Intervention: ID-verify alert
Number of subjects: 4028
Study 22753810 — intervention group
Group type: EXPERIMENTAL
Intervention: ID-reentry function
Number of subjects: 4028
Study 22753810 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4028
Study 20658222 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial training for speech therapists
Number of subjects: 23
Study 20658222 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 23
Study 19101421 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluprednate 2 times a day
Number of subjects: 438
Study 19101421 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluprednate 4 times a day
Number of subjects: 438
Study 19101421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 16478927 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic Decision Board (EndoDB)
Number of subjects: 67
Study 16478927 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard discussion and informed consent process)
Number of subjects: 67
Study 15351795 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (20 mg/day)
Number of subjects: 24
Study 15351795 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide (270 mg/day, 90 mg t.i.d.)
Number of subjects: 24
Study 11018853 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 3TC to ZDV + ddI or ZDV + ddC (addition arm)
Number of subjects: 325
Study 11018853 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to ZDV + 3TC therapy (switch arm)
Number of subjects: 325
Study 11018853 — intervention group
Group type: COMPARATOR
Intervention: Continuation of ZDV + ddI or ZDV + ddC (continuation arm)
Number of subjects: 325
Study 11018853 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 325
Study 9067043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine tape applied for 7 min
Number of subjects: 30
Study 9067043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine tape applied for 15 min
Number of subjects: 30
Study 9067043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine tape applied for 30 min
Number of subjects: 30
Study 9067043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine tape applied for 60 min
Number of subjects: 30
Study 9067043 — intervention group
Group type: COMPARATOR
Intervention: Placebo tape
Number of subjects: 30
Study 8339870 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg daily for 4 weeks
Number of subjects: 39
Study 8339870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3825912 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 to 400 mg 3‐OHQ orally
Number of subjects: 5
Study 3825912 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg quinidine base intravenously
Number of subjects: 5
Study 3825912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 300 to 400 mg 3‐OHQ orally and 150 mg quinidine base intravenously
Number of subjects: 5
Study 28549592 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative pharmacist-physician medication therapy management (MTM) program
Number of subjects: 178
Study 28549592 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 178
Study 27836513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (171 UI/kg, subcutaneously, once a day)
Number of subjects: 259
Study 27836513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%, subcutaneously, once a day)
Number of subjects: 259
Study 25534209 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a CDSS
Number of subjects: 1316
Study 22425375 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) - 1500 pulses, 8 Hz, 3 bars, 4 sessions once a week
Number of subjects: 79
Study 22425375 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 79
Study 20388647 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg every other day to 50 mg daily, adjusted based on serum potassium)
Number of subjects: 3100
Study 20388647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3100
Study 19278083 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.14% SMFP calcium carbonate-based dentifrice
Number of subjects: 998
Study 19278083 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.14% SMFP silica-based dentifrice
Number of subjects: 998
Study 19278083 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride calcium carbonate-based dentifrice
Number of subjects: 998
Study 16468962 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-SRL2 mg
Number of subjects: 975
Study 16468962 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-SRL0.5 mg
Number of subjects: 975
Study 16468962 — intervention group
Group type: COMPARATOR
Intervention: TAC-MMF
Number of subjects: 975
Study 12714091 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef consumption
Number of subjects: 61
Study 12714091 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken consumption
Number of subjects: 61
Study 10961218 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical CT (VAR)
Number of subjects: 50
Study 10961218 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT (sequential mode)
Number of subjects: 50
Study 8928758 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.3 mg.kg‐1.day‐1 sc)
Number of subjects: 26